ReviewHealth science reports2022
Mucormycosis infection in patients with COVID-19: A systematic review.
Review in Health science reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hearing loss and COVID-19: an umbrella review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Pooled it
- Global knowledge, attitude, and practice towards COVID-19 among pregnant women: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2023Pooled it
- Mucormycosis and COVID-19: Unraveling the Interplay of Fungal Infection in a Global Health Crisis: An Overview.Infectious disorders drug targets · 2025Review
- Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study.BMC infectious diseases · 2024Observational
- The prognostic significance of insulin resistance in COVID-19: a review.Journal of diabetes and metabolic disorders · 2024Review
- Review
- Article
- Retraction statement: Mucormycosisco-infection in patients with COVID-19: A systematic review.Health science reports · 2023Article
- Is There a Role for Hyperbaric Oxygen Therapy in Reducing Long-Term COVID-19 Sequelae?Journal of clinical medicine · 2023Article
- Subdural empyema secondary to pansinusitis after coronavirus disease 2019 infection in an immunocompetent patient: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Gut microbiota and COVID-19: A systematic review.Health science reports · 2023Article
- Late Complications of COVID-19; An Umbrella Review on Current Systematic Reviews.Archives of academic emergency medicine · 2023Review
- Effects of Smoking on COVID-19 Management and Mortality: An Umbrella Review.Journal of smoking cessation · 2023Review
- Social stigma during COVID-19: A systematic review.SAGE open medicine · 2023Review
- COVID-19 Co-Infection May Promote Development of Sinusitis Complication in Children.Children (Basel, Switzerland) · 2022Article
- The Impact of the Pandemic on Critical Care in Resource-limited Countries.Iranian journal of medical sciences · 2022Article
- Mucormycosis infection in patients with COVID-19: A systematic review.Health science reports · 2022Review
- Biofilms possibly harbor occult SARS-CoV-2 may explain lung cavity, re-positive and long-term positive results.Frontiers in cellular and infection microbiology · 2022Article
- Study of Management of Mucormycosis in COVID and Post-COVID Patients with Liposomal Amphotericin B its Outcome and Complications in a dedicated COVID Hospital from Eastern India.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
- Retraction · 2023-07-26Compromised Peer Review · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral reports previously described mucormycosis co-infection in patients with COVID-19. As mucormycosis and COVID-19 co-infection might adversely affect patients' outcomes, we aimed to systematically review the related evidence and the subsequent outcomes.
methodsWe conducted a systematic review of relevant articles searching the keywords in the online databases of PubMed, Scopus, Embase, Cochrane, and Web of Science. All the records from the start of the pandemic until June 12th, 2021 underwent title/abstract and then full-text screening process, and the eligible studies were included. We did not include any language or time restrictions for the included studies.
resultsWe found 31 eligible studies reporting 144 total cases of COVID-19 and mucormycosis co-infection. The nose, cranial sinuses, and orbital cavity were the most commonly involved organs, although the cerebrum, lungs, and heart were also involved in the studies. Pre-existing diabetes mellitus (DM), as well as corticosteroid use, were the most commonly identified risk factors, but other underlying conditions and immunomodulatory drug use were also present in several cases. Aspergillus was the most commonly reported micro-organism that caused further co-infections in patients with concurrent COVID-19 and mucormycosis. As most of the studies were case reports, no reliable estimate of the mortality rate could be made, but overall, 33.6% of the studied cases died.
conclusionEarly diagnosis of mucormycosis co-infection in COVID-19 patients and selecting the right treatment plan could be a challenge for physicians. Patients with underlying co-morbidities, immunocompromised patients, and those receiving corticosteroids are at higher risk of developing mucormycosis co-infection and it is crucial to have an eye examination for early signs and symptoms suggesting a fungal infection in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.